SFDA withdraws “Jusprin 81 mg” from market due to quality flaws


RIYADH – The Saudi Food and Drug Authority (SFDA) has withdrawn the medicine “Jusprin 81 mg” from the market due to quality flaws, Saudi Press Agency (SPA) said.

The SFDA has also written to health authorities to stop using the medicine.

This measure has come after the SFDA received information from Julphar, the manufacturing company, that all batches and forms of Jusprin 81 mg have quality flaws. As a result, the Authority has forced Julphar to withdraw all batches and forms of the medicine from all facilities dispensing the drug. It called on those using the medicine to see their doctors.

For those who need more information, the SFDA has called on the public to call the Unified Call Center number 19999 at the SFDA. – SPA